Treatment requirements of rsv bronchiolitis cases under 2 years old


  • yakup söğütlü author
  • Medya Namdar Department of Pediatrics, Burtom Konur Surgical Medical Center, Bursa, Turkey.
  • Olcay Sah Department of Pediatrics, Antalya Kepez State Hospital, Antalya, Turkey
  • Yakup Cag Department of Pediatrics, Kartal Lütfi Kırdar Training and Research Hospital, İstanbul, Turkey.
  • Esma Kepenekli Department of Pediatrics, Pediatric Infection Disease Unit, Pendik Training and Research Hospital, Marmara University Faculty of Medicine, İstanbul, Turkey.
  • Gulcin Kurt Department of Pediatrics, Ankara Research and Treaning Hospital, Ankara, Turkey
  • Elif Cigdem Altunok Department of Biostatistics and Informatics, Yeditepe University Faculty of Medicine, İstanbul, Turkey




Bronchiolitis, Infant, Respiratory Syncytial Virus, Tachypnea, Treatment


Purpose: To evaluate the demographic and clinical characteristics of children and the types and frequencies of treatments given in the setting of respiratory syncytial virus (RSV) bronchiolitis.

Material and Method: Sixty-three children (39 females, 24 males; mean age 8.7 months; range 2 to 24 months) were diagnosed with acute bronchiolitis due to RSV between November 2017 to February 2018. The microbiological diagnosis was made with the detection of RSV antigens by the immunochromatographic assay. Retrospective data included risk factors, symptoms and signs at presentation, laboratory and radiographic findings, and treatment methods.

Results: Fifty-three patients (84.1%) were younger than 12 months. The birth weights were between 1,600 and 4,250 g and the gestational ages were between 31 and 41 weeks. Prematurity was found in 11 patients (17.5%), and comorbid conditions 17 patients (27%).  Hospitalization was required in 34 patients (54%), of whom three patients (4.8%) were further admitted to the intensive care unit. The following treatment modalities were more frequently used: multiple bronchodilators for comorbidities (35.3%), tachypnea (29.7%); inhaled steroid therapy for hypoxemia (90.9%), tachypnea (89.2%); systemic steroid treatment for tachypnea (40.5%); intravenous fluid therapy for tachypnea (78.4%); antibiotherapy for comorbidities (76.5%). Hospitalization was more frequently required in patients with tachypnea (83.8%) and, hypercarbia (83.3%). Treatment methods significantly differed between patients with and without comorbidity, age <12 months, tachypnea. (p<0.05).

Conclusions: The presence of comorbid conditions and tachypnea seems to play a critical role in determining the need for treatment. Tachypnea as a symptom can help predict the need for hospitalization, as well as multiple bronchodilator therapy, steroid therapy, and antibiotic use for the treatment. The presence of tachypnea, hypoxemia, comorbidity, and radiographic infiltration seems to be associated with the need for antibiotics. In addition, the presence of infiltration on chest X-ray, acidosis, hypoxemia, and hypercarbia are also indicators of hospitalization.


Download data is not yet available.



- Holman RC, Shay DK, Curns AT, Lingappa JR, Anderson LJ. Risk factors for bronchiolitis-associated deaths among infants in the United States. Pediatr Infect Dis J. 2003;22(6):483-490. doi:10.1097/01.inf.0000069765.43405.3b

- Piastra M, Caresta E, Tempera A, et al. Sharing features of uncommon respiratory syncytial virus complications in infants. Pediatr Emerg Care. 2006;22(8):574-578. doi:10.1097/01.pec.0000230704.74022.3e

- American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics 2006;118:1774–1793.

- Behrendt CE, Decker MD, Burch DJ, Watson PH. International variation in the management of infants hospitalized with respiratory syncytial virus. International RSV Study Group. Eur J Pediatr. 1998;157(3):215-220. doi:10.1007/s004310050798

- Rotta AT, Wiryawan B. Respiratory emergencies in children. Respir Care. 2003;48(3):248-260.

- Stretton M, Ajizian SJ, Mitchell I, Newth CJ. Intensive care course and outcome of patients infected with respiratory syncytial virus. Pediatr Pulmonol. 1992;13(3):143-150. doi:10.1002/ppul.1950130304

- Kercsmar Carolyn M. Current trends in neonatal and pediatric respiratory care: conference summary. Respir Care. 2003;48(4):459–464.

- MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med. 1982;307(7):397-400. doi:10.1056/NEJM198208123070702

- Murray J, Bottle A, Sharland M, et al. Risk factors for hospital admission with RSV bronchiolitis in England: a population-based birth cohort study. PLoS One. 2014;9(2):e89186. Published 2014 Feb 26. doi:10.1371/journal.pone.0089186

- Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124(6):1694-1701. doi:10.1542/peds.2009-2345

- Drysdale SB, Green CA, Sande CJ. Best practice in the prevention and management of paediatric respiratory syncytial virus infection. Ther Adv Infect Dis. 2016;3(2):63-71. doi:10.1177/2049936116630243

- Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999;354(9178):541-545. doi:10.1016/S0140-6736(98)10321-5

- Stockman LJ, Curns AT, Anderson LJ, Fischer-Langley G. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr Infect Dis J. 2012;31(1):5-9. doi:10.1097/INF.0b013e31822e68e6

- Sanchez-Luna M, Elola FJ, Fernandez-Perez C, Bernal JL, Lopez-Pineda A. Trends in respiratory syncytial virus bronchiolitis hospitalizations in children less than 1 year: 2004-2012. Curr Med Res Opin. 2016;32(4):693-698. doi:10.1185/03007995.2015.1136606

- Paes BA, Mitchell I, Banerji A, Lanctôt KL, Langley JM. A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice. Can Respir J. 2011;18(2):e10-e19. doi:10.1155/2011/493056

- Langley GF, Anderson LJ. Epidemiology and prevention of respiratory syncytial virus infections among infants and young children. Pediatr Infect Dis J. 2011;30(6):510-517. doi:10.1097/INF.0b013e3182184ae7

- Welliver RC Sr, Checchia PA, Bauman JH, Fernandes AW, Mahadevia PJ, Hall CB. Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children. Curr Med Res Opin. 2010;26(9):2175-2181. doi:10.1185/03007995.2010.505126

- Kurji A, Tan B, Bodani J, et al. Children hospitalized with respiratory syncytial virus infection in Saskatchewan pediatric tertiary care centers, 2002-2005. Zhongguo Dang Dai Er Ke Za Zhi. 2014;16(10):1005-1013.

- Turner TL, Kopp BT, Paul G, Landgrave LC, Hayes D Jr, Thompson R. Respiratory syncytial virus: current and emerging treatment options. Clinicoecon Outcomes Res. 2014;6:217-225. Published 2014 Apr 25. doi:10.2147/CEOR.S60710

- Schuh S, Canny G, Reisman JJ, et al. Nebulized albuterol in acute bronchiolitis. J Pediatr. 1990;117(4):633-637. doi:10.1016/s0022-3476(05)80706-1

- Hartling L, Wiebe N, Russell K, Patel H, Klassen TP. Epinephrine for bronchiolitis. Cochrane Database Syst Rev. 2004;(1):CD003123. doi:10.1002/14651858.CD003123.pub2

- Patel H, Platt R, Lozano JM, Wang EE. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst Rev. 2004;(3):CD004878. doi:10.1002/14651858.CD004878

- Gülen F, Yıldız B, Çiçek C, Demir E, Tanaç R. Ten year retrospective evaluation of the seasonal distribution of agent viruses in childhood respiratory tract infections. Turk Pediatri Ars. 2014;49(1):42-46. Published 2014 Mar 1. doi:10.5152/tpa.2014.1121

- Stensballe LG, Devasundaram JK, Simoes EA. Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus. Pediatr Infect Dis J. 2003;22(2 Suppl):S21-S32. doi:10.1097/01.inf.0000053882.70365.c9

- Riccetto AG, Ribeiro JD, Silva MT, Almeida RS, Arns CW, Baracat EC. Respiratory syncytial virus (RSV) in infants hospitalized for acute lower respiratory tract disease: incidence and associated risks. Braz J Infect Dis. 2006;10(5):357-361. doi:10.1590/s1413-86702006000500011

- Ravaglia C, Poletti V. Recent advances in the management of acute bronchiolitis. F1000Prime Rep. 2014;6:103. Published 2014 Nov 4. doi:10.12703/P6-103

- Gadomski AM, Scribani MB. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev. 2014;2014(6):CD001266. Published 2014 Jun 17. doi:10.1002/14651858.CD001266.pub4

- National Collaborating Centre for Women's and Children's Health (UK). Bronchiolitis: Diagnosis and Management of Bronchiolitis in Children. London: National Institute for Health and Care Excellence (NICE); June 2015.

- Fernandes RM, Bialy LM, Vandermeer B, et al. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst Rev. 2010;(10):CD004878. Published 2010 Oct 6. doi:10.1002/14651858.CD004878.pub3

- Cade A, Brownlee KG, Conway SP, et al. Randomised placebo controlled trial of nebulised corticosteroids in acute respiratory syncytial viral bronchiolitis. Arch Dis Child. 2000;82(2):126-130. doi:10.1136/adc.82.2.126

- Mandelberg A, Amirav I. Hypertonic saline or high volume normal saline for viral bronchiolitis: mechanisms and rationale. Pediatr Pulmonol. 2010;45(1):36-40. doi:10.1002/ppul.21185

- Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulised hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev. 2017;12(12):CD006458. Published 2017 Dec 21. doi:10.1002/14651858.CD006458.pub4

- Chen YJ, Lee WL, Wang CM, Chou HH. Nebulized hypertonic saline treatment reduces both rate and duration of hospitalization for acute bronchiolitis in infants: an updated meta-analysis. Pediatr Neonatol. 2014;55(6):431-438. doi:10.1016/j.pedneo.2013.09.013

- Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis [published correction appears in Pediatrics. 2015 Oct;136(4):782]. Pediatrics. 2014;134(5):e1474-e1502. doi:10.1542/peds.2014-2742

- Friedman JN, Rieder MJ, Walton JM; Canadian Paediatric Society, Acute Care Committee, Drug Therapy and Hazardous Substances Committee. Bronchiolitis: Recommendations for diagnosis, monitoring and management of children one to 24 months of age. Paediatr Child Health. 2014;19(9):485-498. doi:10.1093/pch/19.9.485

- Maguire C, Cantrill H, Hind D, Bradburn M, Everard ML. Hypertonic saline (HS) for acute bronchiolitis: Systematic review and meta-analysis. BMC Pulm Med. 2015;15:148. Published 2015 Nov 23. doi:10.1186/s12890-015-0140-x

- Kugelman A, Raibin K, Dabbah H, et al. Intravenous fluids versus gastric-tube feeding in hospitalized infants with viral bronchiolitis: a randomized, prospective pilot study. J Pediatr. 2013;162(3):640-642.e1. doi:10.1016/j.jpeds.2012.10.057

- Kennedy N, Flanagan N. Is nasogastric fluid therapy a safe alternative to the intravenous route in infants with bronchiolitis?. Arch Dis Child. 2005;90(3):320-321. doi:10.1136/adc.2004.068916

- Hall CB, Powell KR, Schnabel KC, Gala CL, Pincus PH. Risk of secondary bacterial infection in infants hospitalized with respiratory syncytial viral infection. J Pediatr. 1988;113(2):266-271.

- Hall CB. Respiratory syncytial virus: A continuing culprit and conundrum. J Pediatr. 1999;135(2 Pt 2):2-7.

- Farley R, Spurling GK, Eriksson L, Del Mar CB. Antibiotics for bronchiolitis in children under two years of age. Cochrane Database Syst Rev. 2014;(10):CD005189. Published 2014 Oct 9. doi:10.1002/14651858.CD005189.pub4

- Vogel AM, Lennon DR, Harding JE, et al. Variations in bronchiolitis management between five New Zealand hospitals: can we do better?. J Paediatr Child Health. 2003;39(1):40-45. doi:10.1046/j.1440-1754.2003.00069.x

- Thorburn K, Harigopal S, Reddy V, Taylor N, van Saene HK. High incidence of pulmonary bacterial co-infection in children with severe respiratory syncytial virus (RSV) bronchiolitis. Thorax. 2006;61(7):611-615. doi:10.1136/thx.2005.048397

- Christakis DA, Cowan CA, Garrison MM, Molteni R, Marcuse E, Zerr DM. Variation in inpatient diagnostic testing and management of bronchiolitis. Pediatrics. 2005;115(4):878-884. doi:10.1542/peds.2004-1299

- Halna M, Leblond P, Aissi E, et al. Impact de la conférence de consensus sur le traitement ambulatoire des bronchiolites du nourrisson [Impact of the consensus conference on the ambulatory treatment of bronchiolitis in infants]. Presse Med. 2005;34(4):277-281. doi:10.1016/s0755-4982(05)83905-3

- Linssen RSN, Schechter MS, Rubin BK. Bronchiolitis therapies and misadventures [published online ahead of print, 2022 Sep 29]. Paediatr Respir Rev. 2022;S1526-0542(22)00066-5. doi:10.1016/j.prrv.2022.09.003

- Alter HJ, Koepsell TD, Hilty WM. Intravenous magnesium as an adjuvant in acute bronchospasm: a meta-analysis. Ann Emerg Med. 2000;36(3):191-197. doi:10.1067/mem.2000.109170

- Alansari K, Sayyed R, Davidson BL, Al Jawala S, Ghadier M. IV Magnesium Sulfate for Bronchiolitis: A Randomized Trial. Chest. 2017;152(1):113-119. doi:10.1016/j.chest.2017.03.002




How to Cite

söğütlü, yakup, Namdar, M., Sah, O., Cag, Y., Kepenekli, E., Kurt, G., & Altunok, E. C. (2023). EVALUATION OF CHILDREN (<2 YEARS OLD) WITH RESPIRATORY SYNCYTIAL VIRUS BRONCHIOLITIS IN TERMS OF DİSEASE COURSE AND THE REQUIREMENTS OF ADDITIONAL TREATMENT: Treatment requirements of rsv bronchiolitis cases under 2 years old. Chronicles of Precision Medical Researchers, 4(1), 22–28. https://doi.org/10.5281/zenodo.7728507